Steven Geller, MD
Pulmonary Disease · Schaumburg, ILNPI 1073597795
Payments from drug & device makers
Across 838 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$3K
- Boehringer Ingelheim$2K
- Mylan Specialty L.p.$524
- Sanofi$494
- Grifols USA, LLC$449
- plus $4K from 33 others
Across 1 payment — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$50
What the payments were for
- Food & beverage$13,757100%
- Education$520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 159 | $3,229 |
| GSK | 271 | $3,174 |
| Boehringer Ingelheim | 106 | $2,051 |
| Mylan Specialty L.p. | 32 | $524 |
| Sanofi | 17 | $494 |
| Grifols USA, LLC | 23 | $449 |
| Mallinckrodt Hospital Products Inc. | 27 | $448 |
| Genentech USA, Inc. | 26 | $410 |
| Electromed, Inc. | 42 | $403 |
| Regeneron Healthcare Solutions, Inc. | 14 | $393 |
| Philips North America LLC | 18 | $362 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $304 |
| Insmed, Inc. | 9 | $245 |
| Advanced Respiratory, Inc | 8 | $151 |
| Baxter Healthcare | 7 | $119 |
| Harmony Biosciences LLC | 4 | $108 |
| Sunovion Pharmaceuticals Inc. | 9 | $105 |
| Johnson & Johnson | 4 | $91 |
| United Therapeutics Corporation | 4 | $86 |
| Covis Pharma GmbH | 3 | $64 |
| Shionogi Inc | 2 | $57 |
| Merck | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Pfizer | 3 | $52 |
| Amgen | 3 | $51 |
| Mayne Pharma Commercial LLC | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $34 |
| Tactile Systems Technology Inc | 1 | $33 |
| Lilly USA, LLC | 2 | $31 |
| La Jolla Pharmaceutical Company | 1 | $26 |
| CSL Behring | 1 | $25 |
| Vapotherm Inc | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| Ambu Inc. | 1 | $20 |
| Inogen, Inc. | 2 | $20 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Circassia Inc. | 1 | $11 |
| Intuitive Surgical | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,809 in reported general payments places this provider in the 80th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 614 | $503,383 |
| Breo ElliptaFluticasone/Vilanterol | 254 | $132,834 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 199 | $114,403 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 80 | $62,450 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 83 | $53,926 |
| Spiriva RespimatTiotropium Bromide | 31 | $20,978 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $16,231 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $14,619 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $12,822 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 14 | $10,806 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 281 | $9,587 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $8,094 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 60 | $6,221 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $3,963 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $3,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $3,174 | $765,2391,092 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $3,229 | $89,487150 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $2,051 | $74,904114 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $53 | $3,28012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Schaumburg
- Amit BhararaSchaumburg$100K
- Neeraj DesaiSchaumburg$52K
- Douglas HogarthChicago$3.1M
- Manu JainChicago$1.9M
- Momen WahidiChicago$1.2M
- Shashi BellamEvanston$1.2M
- Marilyn GlassbergMaywood$1000K
- Steven WhiteChicago$989K
- Ravi KalhanChicago$831K
- Patrick WhittenPeoria$812K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.